Latest Pathkey.AI (ASX:PKY) News

A brutal sell-off in PEXA swamped an otherwise upbeat week for small-cap tech, where contract wins and product launches did the heavy lifting. RocketBoots led the gainers as investors paid up for near-term rollout revenue, while Adveritas rallied on a big push into self-serve SME sales.

Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.

FortifAI’s funding and big claims around faster AI data processing drove the week’s loudest move, while two small caps jumped on price queries. Elsewhere, results season rewarded clear recurring revenue growth, but punished gaps where early buying didn’t stick.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Pathkey.AI has completed a strategic review, bolstered its leadership team, and secured $3.5 million in funding to accelerate growth and broaden its AI platform's applications beyond clinical trials.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

Pathkey.AI has secured A$2.5 million through a placement and launched a nearly A$1 million rights issue to fund expansion of its AI-driven TrialKey platform and pursue strategic acquisitions, alongside key board changes.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.